Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. - Wikidata - wikimedia - TriplyDB

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

http://www.wikidata.org/entity/Q34640239

about

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Progressive multifocal leukoencephalopathy: current treatment options and future perspectives Maraviroc: a review of its use in HIV infection and beyond Graft-versus-host disease: why have we not made more progress?Current and emerging strategies for the prevention of graft-versus-host disease Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis Acute graft-versus-host disease: a bench-to-bedside update.CRK proteins selectively regulate T cell migration into inflamed tissues.Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial The biology of graft-versus-host disease: experimental systems instructing clinical practice.Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.Graft-versus-host disease: state of the science.Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-a A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model.TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521).Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.Management of HIV infection in patients with cancer receiving chemotherapy.T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.Advances in understanding the pathogenesis of graft-versus-host disease.A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study.Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Host genomic influences on HIV/AIDS.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention.The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

P2860

Q26773309-CFBFF45C-6FD5-4ACE-A785-442221D86C83 Q26776236-B0985F23-DADF-4F13-AD8A-5BE1527EFAAF Q26778504-1743086E-82CB-4BF5-BF6C-75481F5858BE Q27012940-E75D30A7-8958-48A9-9D5A-BA071ED243C1 Q27016541-65BD567A-67D1-44B4-A107-A32C99F379FA Q27336127-DF6C950C-2CFE-4549-8AFD-9C5A57D9CC24 Q27687130-5E69176A-AE9A-4808-B335-BE45CB0D672E Q30628412-375B0E33-564C-445A-B039-6FB32AA2F1AA Q33411822-D072FC39-9439-4217-BE94-5C3E1CD45601 Q33917175-14706E42-4F2A-464F-ACBB-4FC358D1D1C6 Q33918485-EF659111-41FB-4503-8550-F8AB4D613B5B Q33919900-333B87C3-69ED-45C5-B828-40B7111680C3 Q33977923-1669E32E-BCB6-404B-91E0-D10292F0EF76 Q34325183-65939106-FFD4-46B1-A0B1-DAFAB5E662A9 Q34390721-66A3CEF5-3FFD-462D-A75A-963723630107 Q34487408-F9C5B88B-6059-43E1-97FB-7F4A1D4E32AD Q34660110-85541FB8-4D44-426E-96F4-C9E2B9C74B0A Q34718135-FB0CE53F-9D4C-472B-9B04-9431245E701B Q34732865-7D09671D-0262-470B-A655-4810EF9881CA Q34858453-82F0071A-8EAA-4190-B385-D541AE49BF6E Q34860077-C16499BA-6BF9-425E-9F0D-E6F5ED75173A Q35008342-8DFA4E6F-741B-40C3-9ACE-8FC95B518065 Q35041966-5B254216-2278-4C60-8F96-ECFDDA9CD414 Q35586614-69327165-BA92-4CA4-8220-F63364AB38F2 Q35712284-241AE1EB-A47E-42BE-B084-2D81192B6E48 Q35755674-6D5A340C-9C58-4625-86DA-5B2C482B45D3 Q35847466-6E7C2061-963A-4F1A-9D9D-EB13990AA0DA Q35971439-B22433E5-F01E-4CBF-A93B-9FEAC944428A Q36041006-6F467557-009F-41AF-AD95-58F738CB802C Q36130498-BD693388-4423-4367-9258-31771AE9A8E8 Q36206861-BBBE3C24-F133-4B3D-A92E-8B969FCA249B Q36263361-8339CE61-8CEA-446C-85EF-0105E8F0CA68 Q36861714-28E7F9F5-50F3-4CE5-B629-AD52F778A73C Q36872470-63582A06-4520-4272-B25D-8F3CB4D56567 Q36891433-801A0129-976B-49A1-9387-67E76B6B82D7 Q36904560-0AE625B8-6453-4567-8BB9-AFE00DCC04A3 Q36905580-BA1EA32B-0B78-4D20-A552-FF65821015FB Q36925951-6D3355E0-FC43-4A8A-8D9A-44BA882248DD Q36938539-6F7E3AF8-D929-4C92-8B90-469C4E87D627 Q37035815-E4508AE4-3466-47C9-BAE8-2C34A8942287

P2860

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

http://www.wikidata.org/entity/Q34640239

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@ast

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@en

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@nl

type

label

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@ast

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@en

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@nl

prefLabel

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@ast

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@en

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@nl

P1433

Q34640239-026DD1E8-317C-4242-9002-7C4EE1CF9932

P1476

Q34640239-318DCD47-DAAE-457D-AC0B-2F2C3718927C

P2093

Q34640239-269D8E9B-F1E8-48F4-9C0E-CA95F20EB51A

Q34640239-27BCAFC4-83D3-4258-8F8F-ECD83A7D34E3

Q34640239-287909AB-FD68-4CF6-BB3D-0FC23232036F

Q34640239-31754A58-9619-41E7-A511-2C85C4B230B4

Q34640239-36DA7276-1B04-41B3-B5D3-170D170116F7

Q34640239-43B57281-B4A9-4647-9237-2D14F7C2FB84

Q34640239-49C4CF24-5EAC-4E6D-B624-282D1BBCE12C

Q34640239-7681A1A3-8BA1-4B46-8F36-753EEFB3B5EA

Q34640239-98E23611-8EBD-4F35-9F16-8E74C46AAD09

Q34640239-AE5917DA-E127-4324-989E-D5D4A6C5726B

P2860

Q34640239-0C4E15A0-FA81-4508-950D-8EFC9D54F57D

Q34640239-0C647BA6-959F-4BD3-A013-EAB46D20FE6B

Q34640239-28EC2E8D-5ADB-40C4-9488-212F2DF5FC91

Q34640239-2CD6F5EC-4D07-47BC-A544-B00365B96CB5

Q34640239-302B5B47-FB96-48FC-9998-F1214AC0586D

Q34640239-324CCA64-8779-48E0-B016-BF6CB738D130

Q34640239-3B79F914-CFD8-4D52-B320-F343808A8797

Q34640239-46E78FBA-7E4B-4CF4-9747-76173BF5DD9C

Q34640239-4DBE5AA4-F057-4781-B864-E3B97DC9FEE5

Q34640239-53311E26-5C09-4FA5-A3CB-205C93958B1E

P304

Q34640239-E54D3B1A-4213-4AED-BC3D-C521FC23E145

P31

Q34640239-E9D6244E-EA70-43F1-9231-63E4A46C8550

P356

Q34640239-B1125D2E-DF76-4109-AED5-63C1D0FE673A

P407

Q34640239-E5742937-E264-4B9A-8D8B-4E6752F53527

P433

Q34640239-C0C730F8-7C4B-44A2-BD64-1D31ABE6CAA4

P478

Q34640239-B976B5ED-4C28-429F-A91D-FF79BD79E8E5

P577

Q34640239-AEC49BB5-5ADD-4230-88A7-67BFD508E35D

P698

Q34640239-B10103A6-3166-43B6-9F16-A946DBA05FF3

P921

Q34640239-64B523B8-E47A-4D78-8FB6-FC764D1E4A90

P932

Q34640239-1D6B2999-869B-4684-A0A9-94CAEC664A09

P356

P1433

The New England Journal of Medicine

P1476

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

@en

P2093

Alison W Loren

http://www.w3.org/2001/XMLSchema#string

Daniel F Heitjan

http://www.w3.org/2001/XMLSchema#string

David L Porter

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Elizabeth O Hexner

http://www.w3.org/2001/XMLSchema#string

Jacqueline Smith

http://www.w3.org/2001/XMLSchema#string

James A Hoxie

http://www.w3.org/2001/XMLSchema#string

Noelle V Frey

http://www.w3.org/2001/XMLSchema#string

Ran Reshef

http://www.w3.org/2001/XMLSchema#string

Robert H Vonderheide

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

Chemokines: a new classification system and their role in immunity

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease

Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation.

Pathophysiologic mechanisms of acute graft-vs.-host disease.

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Graft-versus-host disease treatment: predictors of survival.

P304

135-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1201248

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22784116

http://www.w3.org/2001/XMLSchema#string

P921

P932

3568501

http://www.w3.org/2001/XMLSchema#string